Trial reportFrontiers in medicine2026
Comparison of oliceridine and sufentanil in postoperative pain management for postoperative nausea and vomiting after bimaxillary orthognathic surgery: an exploratory randomized controlled trial.
Trial report in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postoperative nausea and vomiting (PONV) is a prevalent adverse event following bimaxillary orthognathic surgery, with opioids being a significant contributing factor. Oliceridine, a G protein-biased Methods: This prospective, double-blind, randomized controlled exploratory trial was conducted at the Peking University School and Hospital of Stomatology from March to August 2025. A total of 100 eligible patients (ASAI-II, BMI 18-24 kg/m Results: The baseline characteristics were comparable between the groups. The incidence of PONV within 72 h was lower in Group O compared to Group S (40.0% vs. 50.0%; odds ratio [OR] = 0.67, 95% confidence interval [CI]: 0.30-1.47; Conclusion: Oliceridine demonstrated comparable analgesic efficacy and safety to sufentanil, exhibiting numerically lower, albeit not statistically significant, differences in postoperative nausea and vomiting (PONV) and the use of rescue antiemetics. Considering the exploratory nature of this study and the determination of the sample size based primarily on clinical feasibility rather than statistical power, these findings should be regarded as preliminary. Further validation in larger, adequately powered trials incorporating dose-optimization designs is necessary. Clinical trial registration: https://www.chictr.org.cn/showproj.html?proj=257554, Identifier: ChiCTR2500096345.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.